Australia’s Biota, GSK Settle Dispute Over Relenza Promotion
This article was originally published in PharmAsia News
Biota Holdings of Australia and GlaxoSmithKline have reached a $19 million settlement of a dispute over GSK's method of promoting the Australian firm's Relenza (zanamivir) flu drug. Biota had licensed the drug to GSK for global marketing in 2000, but later accused the U.K. firm of failing to promote it properly. Biota sued GSK for $683 million, but settled for less based on advice a trial would be delayed for a long time at greater cost and risk to Biota. Biota said the two firms would resume their cooperation in promoting the drug. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.